MedTrace Logo

Eltrombopag in Second Line Adult Primary Immune Thrombosytopenia

NCT02402998 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2021-08-16

No results posted yet for this study

Summary

A clinical study to evaluate the efficacy of a drug called eltrombopag in adult patients affected of primary immune thrombocytopenia as first treatment to address the disease.

Conditions

  • Primacy Immune Thrombocytopenia

Interventions

DRUG

Eltrombopag

Eltrombopag 50 mg/daily.

Sponsors & Collaborators

  • Gruppo Italiano Malattie EMatologiche dell'Adulto

    lead OTHER

Principal Investigators

  • Francesco Zaja, Pr. · Clinica Ematologica, DISM, Azienda Ospedaliera Universitaria S. M. Misericordia

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-24
Primary Completion
2018-05-22
Completion
2019-08-28

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02402998 on ClinicalTrials.gov